Genitourinary cancers

Our genitourinary cancer specialists are passionate about bringing innovation to patients and supporting the range of clinical studies from early phase to Phase III (registry studies), as well as expanded-access-use clinical studies.

Our team has wide experience as medical leads in different indications (adjuvant, radio chemotherapy, and in metastatic settings) and with different investigational compounds (targeted agents, checkpoint inhibitors, monoclonal antibodies, chemotherapy, and theragnostic). Our colleagues are based in Europe, North America, and the APAC regions, providing a global presence for high-quality medical oversight and monitoring experiences in awarded studies.

An excellent example of our work is a Phase II study for metastatic castrate-resistant prostate cancer (mCRPC) that took place in a highly saturated trial environment. The trial, which included 100+ patients in 50+ sites, involved a complex crossover design. Crucial to the project’s ultimate success were procedural documents provided to the site by the medical monitor. Strategic site selection and study planning established realistic enrollment expectations by tracking completion of competitive trials to bring on new sites. We leveraged established relationships with key opinion leaders in mCRPC and known sites. The full-service solution resulted in enrollment completion two months ahead of the target.